NIOX Group Plc (FRA:82C)

Market Cap	324.31M +9.0%
Revenue (ttm)	53.66M +21.4%
Net Income	6.07M -53.6%
EPS	0.01 -51.6%
Shares Out	n/a
PE Ratio	53.46
Forward PE	23.82
Dividend	0.01 (2.01%)
Ex-Dividend Date	May 15, 2025

Volume	n/a
Average Volume	1,315
Open	0.7550
Previous Close	0.7500
Day's Range	0.7400 - 0.7550
52-Week Range	0.5850 - 0.8850
Beta	n/a
RSI	49.84
Earnings Date	Apr 1, 2026

About NIOX Group

NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled Nitric Oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. N...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 91
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 82C

Financial Performance

In 2024, NIOX Group's revenue was 41.80 million, an increase of 13.59% compared to the previous year's 36.80 million. Earnings were 3.70 million, a decrease of -65.42%.

Financial numbers in GBP